Kodiak Sciences Inc.
KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$37.39
Price-3.37%
-$1.31
1Y
Price
Market Cap
$1.979b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$230.664m
-0.3%
1y CAGR+0.5%
3y CAGR+5.9%
5y CAGREPS
-$4.17
+3.5%
1y CAGR+2.4%
3y CAGR+7.3%
5y CAGRBook Value
$112.101m
$306.006m
Assets$193.905m
Liabilities$55.992m
DebtDebt to Assets
18.3%
-0.3x
Debt to EBITDAFree Cash Flow
-$148.118m
-8.5%
1y CAGR+5.1%
3y CAGR+9.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company